Engineers Gate Manager LP decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO – Get Rating) by 56.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 4,824 shares of the company’s stock after selling 6,372 shares during the period. Engineers Gate Manager LP’s holdings in Novo Nordisk A/S were worth $481,000 as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. Worth Asset Management LLC bought a new stake in Novo Nordisk A/S during the first quarter valued at $32,000. Financial Management Professionals Inc. increased its stake in Novo Nordisk A/S by 95.0% during the third quarter. Financial Management Professionals Inc. now owns 312 shares of the company’s stock valued at $31,000 after purchasing an additional 152 shares during the last quarter. Penserra Capital Management LLC bought a new stake in Novo Nordisk A/S during the third quarter valued at $36,000. Laffer Tengler Investments bought a new stake in Novo Nordisk A/S during the third quarter valued at $37,000. Finally, Old North State Trust LLC bought a new stake in Novo Nordisk A/S during the third quarter valued at $41,000. Institutional investors own 6.09% of the company’s stock.
Novo Nordisk A/S Stock Performance
NVO stock opened at $141.29 on Friday. The company has a market capitalization of $319.74 billion, a P/E ratio of 40.72, a PEG ratio of 1.49 and a beta of 0.47. The company has a 50-day simple moving average of $139.59 and a 200 day simple moving average of $122.46. Novo Nordisk A/S has a fifty-two week low of $95.02 and a fifty-two week high of $145.94. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.29.
Novo Nordisk A/S Increases Dividend
Analyst Ratings Changes
Several equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. boosted their price target on shares of Novo Nordisk A/S from 925.00 to 1,100.00 and gave the company an “overweight” rating in a report on Tuesday, January 3rd. Cowen boosted their price target on shares of Novo Nordisk A/S from $130.00 to $145.00 in a report on Monday, December 12th. Finally, Cowen boosted their price target on shares of Novo Nordisk A/S from $130.00 to $145.00 in a report on Monday, December 12th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $697.78.
Novo Nordisk A/S Profile
Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases.
Featured Stories
- Get a free copy of the StockNews.com research report on Novo Nordisk A/S (NVO)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO – Get Rating).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
